Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Report

Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size, Status and Forecast 2014-2026

  • POSTDATE：Nov 25, 2019
  • PAGES：148
  • REPORT CODE：GMM393509
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Non-Alcoholic Fatty Liver Disease (Nafld) Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.0% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Segmentations:

    By Player:

    • Raptor Pharmaceuticals

    • TCM Biotech International

    • Tobira Therapeutics

    • Daewoong Pharmaceutical

    • Kyorin Pharmaceutical

    • Galmed International

    • Verva Pharmaceuticals

    • Zafgen

    • Novartis AG

    • Metabolic Solutions Development

    • Conatus Pharmaceuticals

    • Phenex Pharmaceuticals

    By Type:

    • Type 1

    • Type 2

    • Type 3

    By End-User:

    • End-User 1

    • End-User 2

    • End-User 3

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 1 from 2014 to 2026

    • 1.3.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 2 from 2014 to 2026

    • 1.3.3 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 3 from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 1 from 2014 to 2026

    • 1.4.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 2 from 2014 to 2026

    • 1.4.3 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Major Types

      • 3.4.1 Market Size and Growth Rate of Type 1

      • 3.4.2 Market Size and Growth Rate of Type 2

      • 3.4.3 Market Size and Growth Rate of Type 3

    4 Segmentation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 1

      • 4.4.2 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 2

      • 4.4.3 Market Size and Growth Rate of Non-Alcoholic Fatty Liver Disease (Nafld) Drug for End-User 3

    5 Market Analysis by Major Regions

    • 5.1 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production Analysis by Top Regions

    • 5.2 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Analysis by Top Regions

    • 5.3 Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.3 France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    6 Product Circulation of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market among Top Countries

    • 6.1 Top 5 Export Countries in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 7.1 Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 7.2 Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    8. UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 8.1 UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 8.2 UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    9. France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 9.1 France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 9.2 France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    10. Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 10.1 Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 10.2 Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    11. Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 11.1 Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 11.2 Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    12. Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 12.1 Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 12.2 Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    13. Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 13.1 Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 13.2 Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    14. Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 14.1 Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 14.2 Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    15. Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 15.1 Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 15.2 Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 16.3.1 Denmark Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 16.3.2 Finland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 16.3.3 Norway Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 16.3.4 Sweden Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 16.3.6 Iceland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 17.3.1 Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 17.3.2 Netherlands Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 17.3.3 Luxembourg Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Landscape Analysis by Top Countries

      • 18.3.1 Estonia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 18.3.2 Latvia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

      • 18.3.3 Lithuania Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Raptor Pharmaceuticals

      • 19.1.1 Raptor Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 TCM Biotech International

      • 19.2.1 TCM Biotech International Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Tobira Therapeutics

      • 19.3.1 Tobira Therapeutics Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Daewoong Pharmaceutical

      • 19.4.1 Daewoong Pharmaceutical Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Kyorin Pharmaceutical

      • 19.5.1 Kyorin Pharmaceutical Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Galmed International

      • 19.6.1 Galmed International Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Verva Pharmaceuticals

      • 19.7.1 Verva Pharmaceuticals Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Zafgen

      • 19.8.1 Zafgen Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Novartis AG

      • 19.9.1 Novartis AG Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Metabolic Solutions Development

      • 19.10.1 Metabolic Solutions Development Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Conatus Pharmaceuticals

      • 19.11.1 Conatus Pharmaceuticals Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Phenex Pharmaceuticals

      • 19.12.1 Phenex Pharmaceuticals Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    The List of Tables and Figures (Totals 75 Figures and 151 Tables)

    • Figure Product Picture

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 1 from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 2 from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of Type 3 from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 1 from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 2 from 2014 to 2026

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate of End-User 3 from 2014 to 2026

    • Figure Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Non-Alcoholic Fatty Liver Disease (Nafld) Drug Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Non-Alcoholic Fatty Liver Disease (Nafld) Drug

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different Types from 2014 to 2026

    • Table Consumption Share of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Type 1

    • Figure Market Size and Growth Rate of Type 2

    • Figure Market Size and Growth Rate of Type 3

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different End-Users from 2014 to 2026

    • Table Consumption Share of Non-Alcoholic Fatty Liver Disease (Nafld) Drug by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of End-User 1

    • Figure Market Size and Growth Rate of End-User 2

    • Figure Market Size and Growth Rate of End-User 3

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production by Major Regions

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production Share by Major Regions

    • Figure Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production Share by Major Countries and Regions in 2014

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Regions

    • Table Europe Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Regions

    • Table Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Germany Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table UK Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table France Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Italy Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Spain Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Poland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Russia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Switzerland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Turkey Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Non-Alcoholic Fatty Liver Disease (Nafld) Drug Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Non-Alcoholic Fatty Liver Disease (Nafld) Drug Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Raptor Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Raptor Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Raptor Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Raptor Pharmaceuticals

    • Table Product and Service Introduction of Raptor Pharmaceuticals

    • Table Company Profile and Development Status of TCM Biotech International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of TCM Biotech International

    • Figure Sales and Growth Rate Analysis of TCM Biotech International

    • Figure Revenue and Market Share Analysis of TCM Biotech International

    • Table Product and Service Introduction of TCM Biotech International

    • Table Company Profile and Development Status of Tobira Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Tobira Therapeutics

    • Figure Sales and Growth Rate Analysis of Tobira Therapeutics

    • Figure Revenue and Market Share Analysis of Tobira Therapeutics

    • Table Product and Service Introduction of Tobira Therapeutics

    • Table Company Profile and Development Status of Daewoong Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Daewoong Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Daewoong Pharmaceutical

    • Figure Revenue and Market Share Analysis of Daewoong Pharmaceutical

    • Table Product and Service Introduction of Daewoong Pharmaceutical

    • Table Company Profile and Development Status of Kyorin Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Kyorin Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Kyorin Pharmaceutical

    • Figure Revenue and Market Share Analysis of Kyorin Pharmaceutical

    • Table Product and Service Introduction of Kyorin Pharmaceutical

    • Table Company Profile and Development Status of Galmed International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Galmed International

    • Figure Sales and Growth Rate Analysis of Galmed International

    • Figure Revenue and Market Share Analysis of Galmed International

    • Table Product and Service Introduction of Galmed International

    • Table Company Profile and Development Status of Verva Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Verva Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Verva Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Verva Pharmaceuticals

    • Table Product and Service Introduction of Verva Pharmaceuticals

    • Table Company Profile and Development Status of Zafgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Zafgen

    • Figure Sales and Growth Rate Analysis of Zafgen

    • Figure Revenue and Market Share Analysis of Zafgen

    • Table Product and Service Introduction of Zafgen

    • Table Company Profile and Development Status of Novartis AG

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis AG

    • Figure Sales and Growth Rate Analysis of Novartis AG

    • Figure Revenue and Market Share Analysis of Novartis AG

    • Table Product and Service Introduction of Novartis AG

    • Table Company Profile and Development Status of Metabolic Solutions Development

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Metabolic Solutions Development

    • Figure Sales and Growth Rate Analysis of Metabolic Solutions Development

    • Figure Revenue and Market Share Analysis of Metabolic Solutions Development

    • Table Product and Service Introduction of Metabolic Solutions Development

    • Table Company Profile and Development Status of Conatus Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Conatus Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Conatus Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Conatus Pharmaceuticals

    • Table Product and Service Introduction of Conatus Pharmaceuticals

    • Table Company Profile and Development Status of Phenex Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Phenex Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Phenex Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Phenex Pharmaceuticals

    • Table Product and Service Introduction of Phenex Pharmaceuticals

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US